ACME Resources and Rapid Dose Therapeutics Announce Court Proceeding Commenced Against Rapid Dose Therapeutics

Toronto and Burlington, Ontario--(Newsfile Corp. - September 28, 2018) - ACME Resources Corp. ("ACME") and Rapid Dose Therapeutics Inc. ("RDT") announce that RDT was served yesterday afternoon with a Statement of Claim issued in the Ontario Superior Court of Justice by CTT Pharmaceutical Holdings Inc. ("CTT") claiming that RDT used confidential information provided by CTT relating to oral thin film technology, breached obligations of confidence and interfered with CTT's economic interests. CTT is seeking an interim and a permanent injunction restraining RDT from using or disclosing confidential information and from selling its QuickStrip or any other oral thin film wafer of medicine. CTT is also seeking damages in excess of $50,000, an accounting and other relief.

RDT denies the allegations made by CTT in its Statement of Claim and believes that CTT's claims are without merit.

On May 29, 2017, RDT entered into an asset purchase agreement ("APA") with CTT to acquire CTT's patents, technology and processes for an oral fast-dissolving drug delivery system. The APA was terminated on October 31, 2017 as a result of RDT being unable to satisfy its due diligence investigations and obtain sufficient comfort with respect to CTT's representations regarding its purported intellectual property.

In response to the claims made by CTT, RDT's Chief Executive Officer, Mark Upsdell stated, "We deny using any of CTT's confidential information as alleged. We have had patent counsel in Canada review CTT's Canadian patents and have been assured that RDT's formulations and processes will not infringe any claim of those patents. Similar opinions have been received from patent counsel in the United States. Accordingly, RDT will continue to protect its own proprietary technologies including by continuing to pursue its own patent applications. RDT believes the CTT claims to be without merit, vindictive, and opportunistic. RDT intends to defend itself vigorously."

Proposed Business Combination

ACME and RDT have proposed a business combination which, when completed, will constitute a reverse take-over of ACME by the shareholders of RDT and the acquisition of RDT by ACME. The previously announced proposed amalgamation involving ACME, its wholly owned subsidiary and RDT (the "Amalgamation") and all of the matters relating to the Amalgamation have been approved by more than 99% of the votes cast by ACME shareholders present in person or represented by proxy at an ACME shareholders meeting held on August 30, 2018 and by 100% of the votes cast by RDT shareholders present in person or represented by proxy at a RDT shareholders meeting held on August 27, 2018. For details of the proposed Amalgamation and other aspects of the proposed reverse take-over transaction, please refer to ACME's news release filed on ACME's profile on SEDAR at www.sedar.com on July 12, 2018 and the management information circular for the ACME shareholders meeting filed on ACME's profile on SEDAR at www.sedar.com on August 9, 2018.

About RDT

RDT is a private Canadian biotechnology corporation providing disruptive proprietary drug delivery technologies designed to improve patient outcomes. RDT's business is to manufacture, distribute and license its orally administrable composition of a film forming agent that delivers a micronized therapeutic to allow the ready absorption of pharmaceutical and other products by patients.

More Information about ACME:

For more information about ACME, visit ACME's profile at www.sedar.com or contact Jorge Estepa, Corporate Secretary, 20 Adelaide Street East, Suite 200, Toronto, Ontario M5C 2T6 Tel: (416) 818-4035.

More Information about RDT:

For more information about RDT, visit: www.rapid-dose.com or contact Rapid Dose Therapeutics Inc at: info@rapid-dose.com, 1121 Walkers Line, Suite 3, Burlington, ON CANADA L7N 2G4 Tel.: (416) 477-1052.

Information in this news release may contain forward-looking information. Statements containing forward-looking information express, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of ACME and RDT as to future events or results and are believed to be reasonable based on information currently available to them. There can be no assurance that forward-looking statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information.